These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16500908)

  • 21. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
    Hong DS; Sebti SM; Newman RA; Blaskovich MA; Ye L; Gagel RF; Moulder S; Wheler JJ; Naing A; Tannir NM; Ng CS; Sherman SI; El Naggar AK; Khan R; Trent J; Wright JJ; Kurzrock R
    Clin Cancer Res; 2009 Nov; 15(22):7061-8. PubMed ID: 19903778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.
    Shacham-Shmueli E; Geva R; Figer A; Bulocinic S; Nalbandyan K; Shpigel S; Atsmon J; Brendel E
    J Clin Pharmacol; 2012 May; 52(5):656-69. PubMed ID: 22232731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.
    Marmé F; Gomez-Roca C; Graudenz K; Huang F; Lettieri J; Peña C; Trnkova ZJ; Eucker J
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):727-737. PubMed ID: 29468456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
    JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
    Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF
    Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
    Rosen LS; Puzanov I; Friberg G; Chan E; Hwang YC; Deng H; Gilbert J; Mahalingam D; McCaffery I; Michael SA; Mita AC; Mita MM; Mulay M; Shubhakar P; Zhu M; Sarantopoulos J
    Clin Cancer Res; 2012 Jun; 18(12):3414-27. PubMed ID: 22510349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.
    Nabhan C; Villines D; Valdez TV; Tolzien K; Lestingi TM; Bitran JD; Christner SM; Egorin MJ; Beumer JH
    Br J Cancer; 2012 Aug; 107(4):592-7. PubMed ID: 22805325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
    Eisen T; Marais R; Affolter A; Lorigan P; Robert C; Corrie P; Ottensmeier C; Chevreau C; Chao D; Nathan PD; Jouary T; Harries M; Negrier S; Montegriffo E; Ahmad T; Gibbens I; James MG; Strauss UP; Prendergast S; Gore ME
    Br J Cancer; 2011 Jul; 105(3):353-9. PubMed ID: 21750549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
    Adjei AA; Molina JR; Mandrekar SJ; Marks R; Reid JR; Croghan G; Hanson LJ; Jett JR; Xia C; Lathia C; Simantov R
    Clin Cancer Res; 2007 May; 13(9):2684-91. PubMed ID: 17473200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
    Nabors LB; Supko JG; Rosenfeld M; Chamberlain M; Phuphanich S; Batchelor T; Desideri S; Ye X; Wright J; Gujar S; Grossman SA;
    Neuro Oncol; 2011 Dec; 13(12):1324-30. PubMed ID: 21954442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
    Mardjuadi F; Medioni J; Kerger J; D'Hondt L; Canon JL; Duck L; Musuamba F; Oudard S; Clausse M; Moxhon A; Machiels JP
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):293-303. PubMed ID: 22752248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
    Ngamphaiboon N; Dy GK; Ma WW; Zhao Y; Reungwetwattana T; DePaolo D; Ding Y; Brady W; Fetterly G; Adjei AA
    Invest New Drugs; 2015 Feb; 33(1):225-32. PubMed ID: 25371323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
    Quintela-Fandino M; Le Tourneau C; Duran I; Chen EX; Wang L; Tsao M; Bandarchi-Chamkhaleh B; Pham NA; Do T; MacLean M; Nayyar R; Tusche MW; Metser U; Wright JJ; Mak TW; Siu LL
    Mol Cancer Ther; 2010 Mar; 9(3):751-60. PubMed ID: 20197396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
    Schultheis B; Neumann H; Roy R; Heuer V; Kummer G; Strumberg D
    Int J Clin Pharmacol Ther; 2012 Jan; 50(1):72-3. PubMed ID: 22192652
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
    Vaishampayan UN; Burger AM; Sausville EA; Heilbrun LK; Li J; Horiba MN; Egorin MJ; Ivy P; Pacey S; Lorusso PM
    Clin Cancer Res; 2010 Jul; 16(14):3795-804. PubMed ID: 20525756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation.
    Shiota M; Eto M; Yokomizo A; Tada Y; Takeuchi A; Itsumi M; Tatsugami K; Uchiumi T; Naito S
    Int J Oncol; 2010 Aug; 37(2):509-17. PubMed ID: 20596679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.
    Federico SM; Caldwell KJ; McCarville MB; Daryani VM; Stewart CF; Mao S; Wu J; Davidoff AM; Santana VM; Furman WL; Pappo AS; Navid F
    Eur J Cancer; 2020 Jun; 132():35-42. PubMed ID: 32325418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.
    Sho T; Nakanishi M; Morikawa K; Ohara M; Kawagishi N; Izumi T; Umemura M; Ito J; Nakai M; Suda G; Ogawa K; Chuma M; Meguro T; Nakamura M; Nagasaka A; Horimoto H; Yamamoto Y; Sakamoto N
    Drugs R D; 2017 Sep; 17(3):381-388. PubMed ID: 28573606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.
    Semrad TJ; Eddings C; Pan CX; Lau DH; Gandara D; Beckett L; Lara PN
    Invest New Drugs; 2012 Oct; 30(5):2001-7. PubMed ID: 22015991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.